HELP Copays Act
Summary
The HELP Copays Act (HR6423) is an early-stage bill that would ban accumulator adjustment programs, forcing insurers to count manufacturer copay assistance toward patient deductibles. This increases insurer drug cost liability, creating a bearish signal for major health insurers like UnitedHealth, Cigna, and Humana. The bill is in early committee stage with no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HELP Copays Act would ban accumulator adjustment programs, increasing insurer drug cost liability.
- 2.Bearish for commercial health insurers: $UNH, $CI, $HUM.
- 3.Bill is early-stage (referred to committee) with companion bill in Senate; no near-term market impact.
Market Implications
The HELP Copays Act is a regulatory risk for commercial health insurers. If passed, it would increase insurers' drug cost liability by forcing them to count manufacturer copay assistance toward patient deductibles. This directly affects UnitedHealth, Cigna ($CI), and Humana ($HUM), which have large commercial plan membership and currently use accumulator programs. The bill is in early committee stage, so no immediate market reaction is warranted. Investors should monitor committee markups and hearings for signs of momentum. The companion bill S864 having hearings in the Senate HELP Committee is a positive signal for passage probability, but the bill remains early-stage.
Full Analysis
-
On December 4, 2025, Representative Kean (R-NJ) introduced the HELP Copays Act (HR6423) in the House. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It has 52 cosponsors and an identical companion bill (S864) in the Senate, which has had hearings in the HELP Committee. The bill is in early legislative stages and has not been marked up or voted on.
-
The bill does not authorize or appropriate any federal funding. It is a regulatory mandate that would change how health insurers treat manufacturer copay assistance. Currently, many insurers use accumulator adjustment programs that exclude manufacturer copay coupons from counting toward patient deductibles and out-of-pocket maximums. This bill would prohibit that practice, requiring insurers to count all copay assistance toward cost-sharing limits. The mechanism is a statutory prohibition on accumulator programs, enforced through ERISA and PHSA requirements.
-
Structural winners are pharmaceutical companies and patients who benefit from copay assistance programs being more effective. Losers are health insurers who lose the cost-control mechanism of accumulator programs. The primary bearish impact is on commercial health insurers with large employer-group and individual plan membership: UnitedHealth Group, Cigna ($CI), and Humana ($HUM). These insurers currently use accumulator programs to limit their drug cost exposure when manufacturers provide copay coupons for high-cost brand drugs. Banning accumulator programs means insurers cover a larger share of drug costs once patients hit their deductibles faster.
-
No real market data is provided for stock prices. The legislative timeline is early: the bill has been referred to two committees and has a companion bill with hearings in the Senate. The 52 cosponsors indicate some bipartisan support, but the bill has not advanced to markup or floor votes. The 119th Congress (2025-2027) has two years remaining, so the bill could progress but faces significant opposition from the insurance industry.
-
Timeline: The next steps are committee hearings and markups in both the House Energy and Commerce and Ways and Means Committees, and the Senate HELP Committee. If the bill passes both chambers and is signed into law, insurers would need to adjust their plan designs and pricing for the next plan year. Given the early stage and insurance industry opposition, passage is uncertain and likely not imminent.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
The HELP Copays Act would require health insurance plans to count copay assistance from drug manufacturers toward patient deductibles and out-of-pocket maximums, preventing insurers from using accumulator adjustment programs.
Who must act
Health insurance issuers offering group or individual health coverage, including Cigna's employer-sponsored and individual plans.
What happens
Insurers lose the ability to exclude manufacturer copay assistance from patient cost-sharing calculations, increasing their liability for drug costs as patients hit deductibles faster and insurers cover a larger share of drug expenses.
Stock impact
Cigna's health insurance segment, covering ~19 million members, would face higher drug cost exposure on plans where accumulator programs are currently used, potentially increasing medical cost ratios by an estimated 0.5-1.5% for affected commercial plans.
What the bill does
The HELP Copays Act would require health insurance plans to count copay assistance from drug manufacturers toward patient deductibles and out-of-pocket maximums, preventing insurers from using accumulator adjustment programs.
Who must act
Health insurance issuers offering group or individual health coverage, including Humana's employer-sponsored and individual plans.
What happens
Insurers lose the ability to exclude manufacturer copay assistance from patient cost-sharing calculations, increasing their liability for drug costs as patients hit deductibles faster and insurers cover a larger share of drug expenses.
Stock impact
Humana's commercial health insurance segment, covering ~5 million members, would face higher drug cost exposure on plans where accumulator programs are currently used, potentially increasing medical cost ratios by an estimated 0.5-1.5% for affected commercial plans.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Improving Seniors’ Timely Access to Care Act of 2025
Protecting Seniors and Stopping Fraudsters Act
Fair Care Act of 2026
Access to Genetic Counselor Services Act of 2025
A bill to amend title XVIII of the Social Security Act to protect against high out-of-pocket expenditures for Medicare fee-for-service benefits, and to amend titles XVIII and XIX of the Social Security Act to enhance programs that protect low-income Medicare beneficiaries.
To provide for civil monetary penalties for violations of mental health parity requirements.
IDA Act of 2026
To direct the Secretary of Labor to require group health plans include certain information on claim denials in annual reports, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →